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Abstract  
BACKGROUND: Leishmaniasis is a parasitic disease induced by a protozoan from the genus Leishmania. No 
effective vaccine has yet been developed against the disease.  
AIM: In this work, two nano-vaccines, TSA recombinant plasmid and dendrimer and poly (methyl methacrylate) 
(PMMA) nanoparticles (as adjuvants), were designed and tested for their immunogenicity in BALB/c mice.  
METHODS: After the plasmid construction and preparation of adjuvants, three intramuscular injections of the 
nano-vaccines (100 µg) and the recombinant TSA protein (20 µg) were subcutaneously performed. Eventually, 
the challenged animals were infected with the parasites (1*10
6
 promastigotes). After the last injections of the 
nano-vaccines, the responses of their antibody subclasses and cytokines were assessed via ELISA method 
before and after the challenge. 
RESULTS: This study revealed that the new nano-vaccines were strong and effective in inducing specific 
antibody and cellular responses and reducing the parasite burden in the spleen compared to the control groups of 
Leishmania major-infected BALB/c mice. 
CONCLUSION: Based on the results, we can suggest that the formulated vaccines are suitable candidates for 
further studies in the field of leishmaniasis control. 
 
 
 
 
Introduction 
 
Leishmaniasis is a widespread parasitic 
disease in many tropical and subtropical regions of 
the world, which is transmitted via the bites of infected 
sand flies. Re-infection is prevented by the immunity 
achieved via cutaneous infection with Leishmania spp. 
This suggests that prophylactic immunisation is 
achievable. No vaccines have been approved to be 
effective against leishmaniasis. DNA vaccination is a 
recent immunisation plan with many potential benefits 
over any other vaccine strategies. DNA vaccines can 
elicit broader immune responses than formal 
vaccines. Thus, to elevate immunity, DNA vaccine is 
complemented with adjuvants. Thiol-Specific 
Antioxidant (TSA) protein is one of the dominant 
antigens of L. major promastigote and amastigote and 
is considered as a primary DNA vaccine candidate 
against leishmaniasis. Many attempts to improve an 
efficient anti-Leishmania vaccine have failed due to 
lacking a suitable adjuvant [1][2].  
Nanoparticles represent a group of 
macromolecular materials that exhibit promising 
therapeutic or prophylactic properties to be used as 
adjuvants for delivering antigens via mucosal surfaces 
and intradermal routes. However, the size of a particle 
affects both antigen delivery and the type of immune 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
230                                                                                                                                                                                                https://www.id-press.eu/mjms/index 
 
responses it produces. As antigen carriers, these 
particles may act as a depot for the regulated release 
of antigens to enhance immune cell responses [3]. 
Dendrimers represent another group of repetitively 
branched molecules with the ability of gene and drug 
delivery. They can also be used in the synthesis of 
monodisperse metallic nanoparticles [4][5]. 
Given the recent developments of 
nanotechnology in the field of drug delivery and the 
unique features of carriers, such as dendrimers, which 
alleviate the problems of low solubility and 
bioavailability of drugs, we applied biocompatible and 
biodegradable dendrimers with polyethylene glycol 
(PEG) core and citric acid branches in this study. 
Today, thanks to nanotechnology, researchers in the 
pharmaceutical industry have developed drug carriers, 
which resolve such problems as low solubility and 
poor absorption of drugs by cells. They can not only 
increase drug bioavailability and help targeted delivery 
to a specific tissue, but also control the amount of 
drug release. The polyvalent natures of peptide 
dendrimers enhance their peptide-specific affinities to 
interact with peptides, proteins, and carbohydrates [6]. 
Despite its approval by the US Food and Drug 
Administration (FDA) for certain clinical human uses, 
poly (methyl methacrylate) (PMMA) as a phagocytised 
particle may trigger strong immune responses by 
inducing the production of inflammatory cytokines [7].  
Therefore, we appraised the effectiveness of 
dendrimer and PMMA as nano-adjuvants with the 
DNA-encoding TSA antigen of L. major in BALB/c 
mice in a bid to obtain a vaccine of improved efficacy 
against leishmaniasis. 
 
 
Materials and Methods 
 
 L. major promastigotes  
L. major MHRO/IR/75/ER, which is an Iranian 
strain separated by Nadim et al. in 1964, was 
obtained from Iranian Pasteur Institute. Promastigotes 
were cultured in RPMI 1640 medium (Sigma
®
) and 
supplemented with 10% heat-inactivated Fetal Calf 
Serum (FCS) (Gibco
®
, BRL) and 100 lg/ml of 
gentamicin (Sigma
®
) at 26°C. The stationary phase 
was catched by centrifugation and used at 1*10
6
 
promastigotes/ml. The procedures of this study were 
also approved by the Ethical Committee of the Faculty 
of Medicine (Iran University of Medical Sciences) with 
code number: IR.IUMS.REC1390.15896. 
 
 
Plasmid construction 
After preparation, TSA recombinant plasmid 
DNA was transmuted into E. coli DH5-α, purified by 
plasmid extraction Kit (Bioneer, Germany), dispersed 
in sterile deionised distilled water, and kept at -20°C 
until used. Then, a purification step was followed by 
using Endo-Free plasmid purification Giga Kit 
(Qiagen, CA, USA) according to the manufacturer’s 
instructions. DNA concentration was concluded by 
taking the dimensions at the Optical Density (OD) of 
260 nm. To ensure that the purified DNA was protein-
free, the OD260/OD280 ratio was obtained to be 1.80-
1.95 [8]. 
 
Preparation of adjuvants  
Here, we introduced a new method for the 
synthesis of G2 dendrimer with PEG core and citric 
acid branches. The method was characterised by 
simplicity and the use of non-toxic materials. Also, in 
this approach, consecutive steps of purification were 
taken, and impurity removal was done in one run 
using Sephadex column without a previous G1 
purification. The method was thus highly fast, cheap, 
and efficient. In this approach, 2 ml of PEG 600 
equivalent to 3.7 mmol and a dry dimethyl sulfoxide 
(DMSO) solvent were utilised in a test tube. An 
amount of 3.7 x 2 mmol of dicyclohexylcarbodiimide 
(DCC) was then added to the test tube to activate the 
reaction, and the lid was immediately closed. The 
reaction tube was stirred for 15 min before the 
addition of an amount of 3.7x2 mM of citric acid 
followed by one h of stirring. Upon skipping a reaction 
stop for G1 purification, we added 3.7x6 mM of DCC 
and the reacting components were further stirred for 
15 min. The stirring was continued again for one h 
after the addition of 3.7 x 6 mM of citric acid and 10 ml 
of DMSO. The reaction was ended by the addition of 
30 ml of double-distilled water. For G2 dendrimer 
purification, we utilised Sephadex column G-75 
(Merck, Germany). To this end, an amount of 6.0 g of 
Sephadex powder was dissolved in 20 ml of double-
distilled water and maintained at ambient temperature 
for 24 h. The Sephadex was then transferred to a 
column and eluted once with double-distilled water. 
Afterwards, G2 dendrimer solution was separated 
from the sedimented DCC using a filter paper and 
transferred to the Sephadex column. The eluted and 
purified solution was thus collected. This step was 
repeated to remove all the impurities and obtain the 
purified water-soluble G2 dendrimer, which was 
lyophilised.  
The required amount of the contributing 
substance was determined with the aid of its 
corresponding stoichiometric relationship, density, and 
molecular weight. Since PEG has two functional 
carboxyl groups capable of binding to citric acid, two 
moles of citric acid was applied per one PEG besides 
DCC as its activator. To ensure the synthesis of the 
required dendrimer, Thin-Layer Chromatography 
(TLC) was performed using a solvent system of 
gradient methanol-chloroform. The size and surface 
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charge of G2 dendrimer was determined by Dynamic 
Light Scattering (DLS) using double-distilled water as 
a solvent. Gamma irradiation polymerisation method 
was applied to produce PMMA nanoparticles in the 
absence of antigens [4]. A nano-vaccine candidate 
was then prepared by loading pcDNA3/TSA 
recombinant plasmid into PMMA nanoparticles. In 
short, 1 Mm of PMMA nanoparticle solution was used 
to cross-link to 10 Mm of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDAC) reagent 
under incubation with soft mixing at room temperature 
for 10 min. Then, 1 ml of plasmid DNA (100 lg/ml of 
the solution) was added to an equal volume of the 
former and placed in a cold room overnight. The 
solution was finally purified by comprehensive 
dialysis, and the resulting PMMA-plasmid DNA 
nanoparticles were suspended in double-purified 
water. The nanoparticle size was determined by using 
a Zeta Sizer (Malvern, UK) (data not shown) [1]. TSA 
recombinant peptide booster (22 KD) was a gift from 
Miss Nargestehrani, a faculty member of the Islamic 
Azad University of Tehran [4][5][6]. 
 
Immunization and experimental infection 
of the mice 
Inbred female BALB/c mice matured 6-8 
weeks were obtained from the Animal Center of 
Pasteur Institute of Iran (Karaj) and treated by the 
National Animal Care and Use protocol adopted by 
the Iranian University of Medical Sciences. The mice 
were divided into 3 test (T) and four control (C) groups 
(20 mice/group). The test group received DNA 
vaccine (pcDNA3/TSA), nano-vaccine 
(pcDNA3/TSA+dendrimer), and nano-vaccine 
(pcDNA3/TSA+PMMA), while the control group 
received pcDNA3, dendrimer, PMMA, and PBS at the 
doses of 100 µg. For experimentation, the mice were 
anesthetized by an intraperitoneal injection of 25 µl g
-1
 
of a combination of 10% ketamine and 2% xylazine. 
All the treatments were intramuscularly administrated, 
and the injection sites were immediately subjected to 
8 electric 60-V pulses for 20 ms at a 200-ms interval 
by using a BTX ECM 830 generator (Harvard 
Apparatus, USA) equipped with tweezer-type 
electrodes (CUY 650, Sonidel Limited, Ireland). 
Immunization of the mice was done by injecting 50 µl 
of PBS into each anterior tibialis muscle. The 
immunisation schedule was performed with three 
inoculations of equal doses of DNA, dendrimer, and 
PMMA at 3-week intervals. The booster peptide (20 
µg) and incomplete Freund’s adjuvant was 
subcutaneously injected two weeks after the injection 
of the last nano-vaccines. The immunised mice were 
intradermally challenged with 1*10
6
 promastigotes of 
L. major at the base of their tails three weeks later. 
The animals were then sacrificed after five post-
challenge weeks, and their serum samples and 
spleens were immunologically analyzed [7][8][9]. 
 
Lymphocyte proliferation assay 
The spleen of each sole mouse was 
dismembered and suspended in sterile, cold 
Phosphate-Buffered Saline (PBS) containing 2% Fetal 
Bovine Serum (FBS). The Red Blood Cells (RBCs) 
were lysed, and a single-cell suspension was 
prepared in RPMI 1640 (Gibco, Germany) at 3*10
6
 
cells/ml, which was complemented with 10% of FBS, 
4 mM of L-glutamine, 1 mM of sodium pyruvate, 50 
µm of 2-ME, 100 µg/ml of streptomycin, and 100 IU/ml 
of penicillin. Flat-bottom 96-well culture plates were 
used to dispense 100 µl of the cell suspension 
motivated with ten µg/ml of the recombinant TSA 
protein expressed in E. coli cells for antigen recall. 
Phytohemagglutinin-A (5 µg/ml, Gibco) and 
unmotivated wells were utilized as the positive and 
negative controls, respectively. The whole culture 
medium was similarly applied as blank. All the tests 
were done in triplicate. The plates were incubated for 
72 h before supplementing 100 µl of 5-Bromo-2-
deoxy-uridine (BrdU) labelling solution into each well 
and incubating them for 18 further hours. The plates 
were then subjected to centrifugation to remove the 
culture medium before drying and fixing the wells with 
100 µl of fixation/ permeabilisation buffer. 
Subsequently, each well received 100 µl of anti-BrdU 
antibody before washing the plates four times and 
supplementing them with tetramethylbenzidine (TMB) 
substrate. The test was halted by concluding 100 µl of 
2 NH2SO4. The OD of each well was assessed at 450 
nm. The stimulation indices were estimated in accord 
with the following formula: OD of the stimulated 
well/OD of the unstimulated well. 
 
Cytokine evaluation before and after the 
challenge with L. major  
The single-cell suspension (3*10
6
 cells/ml) 
derived from each mouse spleen was dispensed into 
the 24-well plates, aroused in vitro with ten µg/ml of 
recombinant TSA protein, and incubated in 5% CO2 at 
37°C. After 72 hrs of antigen recall, the supernatants 
were obtained by centrifugation at 300*g for 10 min 
and supplied at -70°C for cytokine analysis. Then, 
using commercial ELISA Kits (Mabtech, Sweden) 
according to the manufacturer’s instructions, IFN-γ 
and IL-4 cytokines were quantified. Each cytokine was 
quantified as pg/ml based on the plotted standard 
bend. 
 
ELISA of the total antibodies and the 
subclasses of IgG1, IgG2a 
Assay of the sera of the empirical groups was 
done using an optimised indirect ELISA approach to 
assess humoral immune responses based on the 
specific antibodies before and after L. major 
challenge. In short, 100 µl of antigen (10 µg/ml) in 
PBS buffer was supplemented into 96-well ELISA 
MaxiSorp plates (Nunc, Naperville, IL) and incubated 
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at 37°C for 24 h. After being washed with PBS 
containing 0.05% Tween 20 (washing buffer), the 
plates were blocked with 5% skimmed milk in PBS 
(blocking buffer) at 37°C for one h. The plates were 
again rinsed with a rinsing buffer before the addition of 
100 µl of the diluted sera (1/100) to each well and 
then incubated at 37°C for two h. The wells were 
rinsed five times and incubated with 100 µl of the 
diluted (1/7,000) anti-mouse sera conjugated to HRP 
(Sigma, USA) for two h. The wells were again rinsed 
five times before further incubation with 100 µl of TMB 
substrate in the dark for 30 min. The reaction was 
then stopped by the addition of 2 N H2SO4. The ODs 
were estimated with an ELISA plate reader at λ 450 
nm. Using the secondary antibodies of goat anti-
mouse IgG1 and IgG2a (Sigma, USA) based on the 
manufacture’s instruction, the specific subclasses of 
IgG1 and IgG2a were detected [10][11]. 
 
Parasite load distinction 
The parasite burden was determined by 
sacrificing three mice per each group, which had been 
challenged seven weeks earlier. Then, their spleens 
were drained using the limiting dilution method. 
Briefly, a slice of a spleen was removed and weighed 
to be homogenised with a tissue grinder in 2 ml of 
RPMI 1640 medium (Gibco, Germany) complemented 
with 20% heat-inactivated FCS and Gentamicin 
(0.1%). Serial dilutions were prepared in 96-well micro 
titration plates under sterile conditions. After seven 
days of incubation at 26°C, the plates were examined 
using an inverted microscope at a magnification of 
40*. The presence or absence of mobile 
promastigotes was recorded in each well. The last 
titer was the last dilution, in which the number of 
parasites per gram was estimated in the following 
way: _log10 (parasite dilution/tissue weight) [2][10]. 
 
Statistical analysis 
The significance of the differences among 
various groups was tested using the one-way ANOVA 
test. Besides, Post-hoc LSD test was utilised to 
compare the means of the different groups under 
treatment. The statistics were regarded significant at 
P < 0.05. 
 
 
Results 
 
Lymphocyte proliferation assay 
Lymphocyte proliferation analysis before the 
challenge through BrdU method revealed no 
significant differences between the vaccinated groups 
after three injections of DNA and the nano-vaccines 
(pcTSA+dendrimer and pcTSA+PMMA and pcTSA) at 
P = 0.337 although 3 test groups demonstrated 
significantly different proliferative activities from those 
of the control groups at P < 0.001. After challenging 
with L. major, the immunised groups displayed no 
significant differences among themselves (P > 0.549), 
but all produced higher degrees of proliferation 
responses than those of the control groups (P < 
0.001) (Fig. 1). 
 
Figure 1: Lymphocyte proliferation responses before and after the 
challenge: The mice were immunised with DNA vaccine with or 
without a dendrimer and PMMA (n = 5 mice per group) in the DNA 
prime/peptide raising plan. The four groups of mice were injected 
with pcDNA3 vector, dendrimer, PMMA, and PBS as the negative 
controls (n=4 mice per group). Proliferative reactions were followed 
for the unique mice in triplicate and evaluated using BrdU method 
as represented in the section of "Materials and Method". The data 
depict mean ± SD (95% C.I.). *P < 0.001 considered for the 
vaccinated groups before and after the challenge showed a 
significantly higher rank for rapid growth compared to those of the 
control groups 
 
 
The models of IL-4 and IFN-γ cytokines 
In an attempt to appraise the pattern of cytokine 
secretion caused by vaccination, the special mouse 
splenocyte culture was re-stimulated in vitro with 
recombinant TSA protein and cleansed in E. coli cells 
(data not shown). The collected supernatants were 
tested for IFN-γ and IL-4 quantities causing the types 
of the induced immune responses (T helper one vs T 
helper 2). The results represented that before the 
challenge, IFN-γ secretion level was significantly 
higher in the vaccinated than in the control groups 
(P<0.001) meaning that immunisation increases IFN-γ 
production by lymphocytes. Behind the challenge, 
IFN-γ level remarkably augmented in the mice 
immunized with the nano-vaccines 
(pcTSA+dendrimer, pcTSA+PMMA) compared to the 
control groups and those immunized with DNA 
vaccine (PcTSA) (P<0.001) (Fig. 2a). Before the 
challenge, the mice immunized with the DNA vaccine 
and formulated with the nanoparticles revealed a 
significant enhancement of IL-4 level produced by 
lymphocytes compared to the control and DNA-
vaccinated mice groups (P < 0.001). However, after 
the challenge with L. major, no statistically significant 
differences between the test and control groups were 
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noticed (P > 0.733) regarding IL-4 production (Fig. 
2b). 
a)  
b)  
Figure 2: Cytokine yields (IFN-γ (a) and IL-4 (b)) by the spleen cells 
of BALB/c mice after the immunization periods and the challenge: 
The mice were immunized with DNA vaccine with or without the 
dendrimer and PMMA (n = 5 mice per group) in the DNA 
prime/peptide life plan. The four groups of mice were injected with 
pcDNA3 vector, dendrimer, PMMA, or PBS as the controls (n=4 
mice per group). Cytokine analyses were observed during the study 
by using ELISA approach as mentioned in the section of "Materials 
and Methods". The tests were carried out in duplicate for the special 
mice. The merits represent mean ± SD (95% C.I.). *P < 0.005 was 
considered for the nano-vaccine groups compared to all the other 
groups. *P < 0.001 was regarded for the immunised groups 
compared to the control groups. *P < 0.001 for the groups of 
pcTSA+dendrimer and pcTSA+PMMA was considered to be similar 
to all the other groups after the challenge with L. major (Fig. 2a). *P 
< 0.025 was taken for the nano-vaccine groups compared to all the 
other groups before the challenge. *P < 0.011 for the vaccinated 
groups was regarded to be similar to the PBS group after the 
challenge (Fig. 2b) 
 
Antibody responses 
In general, the immunised groups showed a 
significant rise in their total antibody productions 
before the challenge compared to the control groups 
(P < 0.003). After the challenge, the mice produced 
elevated levels of antibodies and had been thus 
immunised with the nano-vaccines, but they did not 
indicate statistically significant differences among 
themselves (P > 0.059). The nano-vaccines exhibited 
a significant rise in the total antibody production after 
the challenge in comparison to the control and 
vaccinated groups (P < 0.003) (Fig. 3a,b). The effects 
of IgG isotyping demonstrated that the test and control 
groups had similar IgG1 levels before the challenge 
with no significant differences between them (P > 
0.059). However, after the challenge, all the 
immunised groups produced significantly increased 
IgG1 isotypes as compared to the control groups 
(P<0.030). Before and after the challenge, IgG2a titer 
was more significant in the immunised than in the 
control groups (Fig. 3c,d).  
 
a)  
b)  
c)  
d)  
Figure 3: Specific antibody production against TSA recombinant 
protein in BALB/c mice immunized with DNA vaccine and nano-
vaccines before the challenge (a) and after the challenge (b): The 
specific total IgG, IgG1, and IgG2a were measured through ELISA 
approach as mentioned in the section of "Materials and Methods". 
The sera obtained from each group were diluted 1:200 and 
assessed for the presence of IgG1 and IgG2a. Specific changes in 
IgG1 (c) and IgG2a (d) levels were detected throughout the study. 
TMB substrate was employed for the detection and OD was 
determined at 450 nm. Mean ± SD (95% C.I.) is represented 
throughout the data 
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Splenic parasite burden 
The splenic parasite burden assays of all the 
empirical groups revealed that the numbers of viable 
splenic parasites were different among the vaccinated 
and unvaccinated groups following the immunisation 
and seven weeks after the challenge with L. major. 
The immunised mice displayed a significantly lower 
number of alive parasites compared to the control 
groups (P < 0.001) (Fig. 4). 
 
Figure 4: Parasite burden associated with DNA vaccine and nano-
vaccines in the prime/boost strategy and control groups seven 
weeks after the challenge: Calculations of the total numbers of the 
viable parasites within the spleens of the infected animals were 
done based on parasite dilution per tissue weight. Mean ± SD was 
used to represent the values obtained for the individual mice (n = 
3). A significantly less parasite burden was found in the spleens of 
the vaccinated mice compared to those of the control groups (*P < 
0.001) 
 
 
Discussion 
 
In the present study, we attempted to design 
novel nano-vaccines containing TSA plasmid DNA 
and estimate their immunogenicities in BALB/c mice. 
Currently, there are no effective vaccines available to 
produce a protective response against leishmaniasis. 
This is despite the fact that many vaccination 
strategies ranging from involving the killed parasites to 
recombinant antigens or DNA vaccines have been 
tested. Antigens, such as recombinant proteins induce 
only antibody responses while DNA vaccines involve 
both MHC-I and MHC-II pathways. Therefore, DNA 
vaccines can cause strong, long-lasting, and effective 
humeral and cellular immunities. The prime-boost 
immunisation method can influence the quality and 
quantity of immune responses. However, certain 
approaches are needed to increase the qualities and 
efficacy of DNA vaccines, such as in vivo 
electroporation. TSA as the immune-dominant antigen 
of L. major is antigenic in murine and human systems 
and induces CTL activity and safety against the 
parasite. Excellent protection against leishmaniasis 
has been reported for the recombinant leishmanial 
antigens LmSTI1 and TSA [12][13][14]. Nevertheless, 
using an adjuvant seemed necessary to boost any 
modern vaccines against leishmaniasis [15]. The 
results of this research revealed that the mice 
immunization with the nano-vaccines and DNA 
vaccine increased humoral and cellular responses as 
compared with the control groups. 
In this investigation, we used dendrimer 
nanoparticles as adjuvants to elicit stronger immune 
responses to the candidate vaccines. This is because 
dendrimers had nowadays several practical 
applications in medicine and attracted the attentions 
of many researchers to obtain novel synthetic designs 
with reduced toxicities. 
 An anionic PEG-citrate G2 dendrimer was 
chosen because of its biocompatibility and 
biodegradability. Dendrimers are nano-carriers with a 
high potential to carry hydrophobic drugs and increase 
their solubilities in water as well as their cellular 
uptakes. The unique properties of dendrimers, 
including monodispersity and surface modification 
capability along with their sizes and structure sets, 
have made them ideal candidates for drug delivery. 
Scientific research during the last two decades has 
shown that dendrimers are appropriate and effective 
carriers for drug delivery and enhancement of the 
mobilities of hydrophobic drugs. Another feature of a 
dendrimer is its possession of suitable spaces, within 
which various hydrophobic and hydrophilic drug 
molecules can be accommodated. The presence of 
multiple well-known functional groups on the surface 
of these spherical particles make them as suitable 
carriers to fit various drug molecules or ligands and 
consequently enable them to help a targeted drug 
delivery. The results of the studies performed on 
these dendrimers have shown that these chemicals 
have great potentials for use in drug delivery systems. 
Shafiee Alavijeh et al. examined cell death 
mechanisms (apoptosis and necrosis) caused by a 
dendrimer in HT1080 cell lines. Based on their results, 
dendrimers had no significant detrimental effects at a 
concentration of 0.5 mg/ml. They stated that these 
hybrid structures would be a very large potentiality for 
application in the various fields of nano-medicine. In 
another study carried out by Haririan et al., two 
conjugates were prepared from cisplatin in aqueous 
solutions with the two generations (G1 and G2) of 
biodegradable anionic citric acid dendrimers. Based 
on the in vitro results obtained from their research, a 
conjugate of G2+platinum had higher toxicity to 
cancer cells than that of G1+platinum and cisplatin 
and hence showed a better therapeutic effect. They 
stated that these conjugates with such a high 
potentiality and minimum hemolysis are good 
candidates as new and effective anti-tumour agents. It 
should be noted that some types of dendrimers, such 
as viologen with a chemical structure containing 
bipyridinium salts or other structures like Caminade, 
PAMAM, polyanionic phenyl dicarboxylic acid 
(BRI6195), or carbosilane have shown antiviral 
properties, particularly against HIV-1 with EC [50] = 
0.26 ± 0.08 μM (e.g., viologen). The mechanism 
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behind these observations was reported to be caused 
by an interference with viral replication or gp-120 
protein function, especially in the case of PAMAM. 
This would strengthen the hypothesis that the 
simultaneous use of dendrimeric structures and 
curcumin can produce synergistic or additive effects. 
In this research, PEG was chosen due to its 
environmental compatibility and biodegradability, as 
well as its easy reaction with citric acid and 
constitution of the core of a dendrimer. The presence 
of citric acid in the structure of this dendrimer as a 
macromolecule, which can be subjected to 
metabolism by the cellular citric acid cycle upon 
entering the cell, has made it environmentally 
compatible and biodegradable. The dendrimer is not 
cytotoxic in therapeutic doses depending on the study 
type because of its size (about 80 nm) and negative 
charge. Cells have negative charges similar to a 
subjected dendrimer and thus cell surface absorption 
as the main cause of cell toxicity may not occur. In 
this study, DCC was applied instead of chlorinated 
compounds, such as dichloromethane, which is 
usually used to activate synthetic reactions. 
Chlorinated compounds are highly toxic and cause a 
serious damage to human respiratory system, but 
DCC has a much lower toxicity and can be thus 
considered advantageous in our method. The 
obtained product was a two-generation dendrimer 
(G2), which was completely soluble in water and 
could, therefore, be a good candidate to increase the 
solubility of water-insoluble drugs. Studies have 
shown that this dendrimer has no unfavourable effects 
on cells at a concentration of 5.0 mg/ml. In this 
research, we employed a new method to synthesize 
nanoparticles, which not only shortened the reaction 
and production times but also enabled the use of less 
toxic materials [6][16].  
The nanoparticle conjugates of the dendrimer 
produced valid antibody responses and protections 
against some antigens. Among numerous 
nanoparticles, those which are biodegradable, safe, 
and simple and easy to be produced can be selected 
for the drug delivery under study [17][18][19][20]. The 
findings of the previous studies indicated that 
dendrimers have antibacterial effects. In this work, 
PMMA nanoparticle was utilised as an adjuvant to 
enhance specific humoral and cellular immune 
responses to our candidate vaccines due to its good 
antibody responses in addition to its conferring higher 
stability to the vaccines. The utilisation of PMMA 
adjuvant in split influenza vaccines demonstrated a 
safety record and excellent and powerful protection 
[21][22]. This nanoparticle may also enhance humoral 
responses against Hiv-2. Some authors suggested 
that PMMA adjuvant can increase antibody production 
and hence the efficacy of candidate vaccines [23][24]. 
Our findings revealed that both the specific IgG1 and 
IgG2a were augmented upon immunisation with 
PMMA nano-vaccine and dendrimer. Considering that 
IgG1 and IgG2a are Th2 and Th1 markers, 
respectively, this funding was of prime importance. 
Campos-Neto et al. reported that immunisation of 
BALB/c mice with a TSA plasmid DNA influenced 
elevated titers of particular IgG1 and IgG2a antibodies 
vs. Leishmania [25][26][27]. Other studies have shown 
that the use of nanoparticles and a major raising plan 
increases protective immunity against Leishmania 
infection in animal models [26][28]. In this research, 
we showed that a dendrimer and PMMA can boost the 
efficacy of DNA vaccines encoding TSA against L. 
major disease and bring out immune responses to the 
delivered antigen. Our nano-vaccines were productive 
for lowering parasite load in the spleens of BALB/c 
mice infected with Leishmania major as compared to 
the control groups.  
In conclusion, the vaccine formulation 
suggested in this investigation may provide a way to 
be paved for obtaining excellent candidates against 
Leishmania through further research. 
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